DNA strand intertwining with a cityscape

Precision Oncology: Navigating Myths and Maximizing Benefits for a Healthier Future

Samir D’Costa in Health & Wellness December 2025 • 4 min read.

"Uncover how to move forward from old misconceptions, precision oncology offers tailored treatments for a healthier future."

Precision oncology, which tailors cancer treatment to individual patients based on their unique genetic and molecular profiles, holds immense promise for improving outcomes. However, misconceptions and outdated statistics can hinder its progress. A recent article highlighted concerns about the limited percentage of patients benefiting from genome-driven treatments, sparking debate about the true potential of precision oncology.

This article addresses these concerns, emphasizing the importance of interpreting data with caution and considering the evolving landscape of cancer treatment. It underscores the need to move beyond historical statistics and embrace innovative strategies to maximize the benefits of precision oncology for a healthier future.

We aim to debunk prevailing myths surrounding precision oncology, outline actionable steps for improvement, and empower patients and healthcare providers with the knowledge needed to navigate this rapidly advancing field. By focusing on evidence-based approaches and continuous innovation, we can unlock the full potential of precision oncology and transform cancer care.

Debunking Myths: How Precision Oncology is Evolving

DNA strand intertwining with a cityscape

One of the primary concerns raised is the perception that only a small percentage of cancer patients benefit from precision oncology. For example, the statement that only 6.62% of patients benefited from genome-driven treatments in 2018 can be misleading if not properly contextualized. This figure is often based on retrospective data and sensitivity analyses that may not reflect current clinical trial designs and advancements.

Historical data, such as the 16% response rate to trastuzumab monotherapy in HER2-positive breast cancer, does not account for the significant improvements achieved through combination therapies and refined patient selection criteria. Modern approaches, which combine trastuzumab with chemotherapy and target patients with HER2 amplification, yield much higher response rates, ranging from 42% to 72%.

Improved Combination Therapies: Combining targeted drugs with chemotherapy enhances efficacy.
Refined Patient Selection: Identifying patients with specific genetic markers ensures better treatment outcomes.
Evolving Treatment Strategies: Continuous advancements in drug development and treatment protocols lead to better results.

Furthermore, older statistics, such as the 10% response rate to gefitinib in unselected non-small cell lung cancer patients, fail to capture the impact of subsequent research and patient stratification. Today, identifying specific genetic mutations allows for more precise targeting and improved outcomes. By addressing these misconceptions, we can foster a more accurate understanding of the true potential of precision oncology.

Embracing Innovation for a Healthier Future

Precision oncology offers the promise of tailored treatments, it is vital to embrace ongoing innovation, interdisciplinary collaboration, and continuous learning. By moving beyond outdated statistics and preconceived notions, healthcare providers, patients, and researchers can work together to unlock the full potential of precision oncology. By focusing on genomics, personalized medicine, and patient-centered strategies, we can transform cancer care and create a healthier future for all.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1001/jamaoncol.2018.5064, Alternate LINK

Title: Moving Precision Oncology Forward Amid Myths And Misconceptions

Subject: Oncology

Journal: JAMA Oncology

Publisher: American Medical Association (AMA)

Authors: Filip Janku, Kenneth R. Hess, Timothy A. Yap

Published: 2018-12-01

Everything You Need To Know

What is precision oncology, and how does it differ from traditional cancer treatments?

Precision oncology tailors cancer treatments to individual patients based on their unique genetic and molecular profiles. Unlike traditional treatments, which often use a one-size-fits-all approach, precision oncology leverages genomics and personalized medicine to identify the most effective therapies for each patient. This targeted approach aims to maximize benefits and minimize side effects by focusing on the specific characteristics of a patient's cancer.

Why is it important to move beyond outdated statistics when evaluating the effectiveness of precision oncology?

Historical data, such as the 6.62% benefit rate from genome-driven treatments in 2018, may not accurately reflect current advancements in precision oncology. These figures often come from retrospective data and analyses that don't account for improved clinical trial designs, refined patient selection, and the development of combination therapies. Modern approaches, such as combining trastuzumab with chemotherapy for HER2-positive breast cancer, demonstrate significantly higher response rates compared to older monotherapy approaches.

How do improved combination therapies enhance the effectiveness of precision oncology?

Improved combination therapies, a key element of precision oncology, involve using multiple drugs that work together to target cancer cells more effectively. For example, combining trastuzumab with chemotherapy in HER2-positive breast cancer has dramatically increased response rates. This approach is in contrast to older methods, where single-drug treatments yielded lower success rates. By combining different therapies, precision oncology can overcome drug resistance and target cancer cells from multiple angles.

How does the use of genomics and personalized medicine contribute to better outcomes in cancer treatment?

Genomics and personalized medicine are central to precision oncology. By analyzing a patient's unique genetic and molecular profile, healthcare providers can identify specific mutations and markers that drive cancer growth. This allows for the selection of targeted therapies tailored to those specific characteristics. For example, identifying specific genetic mutations in non-small cell lung cancer patients allows for more precise targeting and improved outcomes, moving beyond the limited success of older treatments. This approach ensures that patients receive the most appropriate and effective treatments based on their individual needs.

What are the key steps to maximize the benefits of precision oncology and create a healthier future for all?

To maximize the benefits, the field must embrace ongoing innovation, interdisciplinary collaboration, and continuous learning. This includes focusing on genomics, personalized medicine, and patient-centered strategies. It is crucial to move beyond outdated statistics and embrace new approaches. Furthermore, continuous advancements in drug development and treatment protocols lead to better results. Healthcare providers, patients, and researchers should work together to ensure that the full potential of precision oncology is realized, transforming cancer care for a healthier future.